TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.
Epistemonikos ID: 7fe344d10913cc652b1a6484bf35ae567f73acd1
First added on: May 05, 2024